An Open-Label Phase 2 Safety and Efficacy Study of EPI-743 (Vincerinone) in Children With Pearson Syndrome.
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2018
Price : $35 *
At a glance
- Drugs Vatiquinone (Primary)
- Indications Mitochondrial disorders
- Focus Therapeutic Use
- Sponsors BioElectron Technology
- 31 Aug 2018 Biomarkers information updated
- 23 Nov 2015 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
- 21 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.